Clinical Trial

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated March 21, 2025 (before its estimated April 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of intravitreal injection of EXG202 in subjects with neovascular age-related Macular Degeneration (nAMD).
Trial Details
NCT Number NCT06888492
Lead Sponsor Guangzhou Jiayin Biotech Ltd
Conditions Wet Age-related Macular Degeneration (wAMD), Wet Age-related Macular Degeneration
Enrollment 8 participants
Start Date 2025-03-28
Primary Completion 2026-04-25 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-21